Detailed Information

Cited 8 time in webofscience Cited 9 time in scopus
Metadata Downloads

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Authors
Song, Do SeonKim, WonAhn, Sang HoonYim, Hyung JoonJang, Jae YoungKweon, Young OhCho, Yong KyunKim, Yoon JunHong, Gun YoungKim, Dong JoonJung, Young KulSohn, Joo HyunLee, Jin-WooPark, Sung JaeLee, Byung SeokKim, Ju HyunKim, Hong SooYoon, Seung KewKim, Moon YoungLee, Kwan SikLim, Young SukLee, Wan SikYang, Jin MoKim, Kyun-HwanHan, Kwang-HyubUm, Soon Ho
Issue Date
Apr-2021
Publisher
대한간학회
Keywords
Besifovir; Hepatitis B, Chronic; Drug resistance; Bone mineral density; Nephrotoxicity
Citation
Clinical and Molecular Hepatology, v.27, no.2, pp.346 - 359
Indexed
SCIE
SCOPUS
KCI
Journal Title
Clinical and Molecular Hepatology
Volume
27
Number
2
Start Page
346
End Page
359
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/53096
DOI
10.3350/cmh.2020.0307
ISSN
2287-2728
Abstract
Background/Aims: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients. Methods: Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV). Results: Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group. Conclusions: BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jung, Young Kul photo

Jung, Young Kul
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE